What are the current recommendations for biomarker‑guided diagnosis and disease‑modifying therapy in patients with cognitive decline due to Alzheimer disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latest Update on Cognitive Neurology: Biomarker-Guided Diagnosis and Disease-Modifying Therapy in Alzheimer Disease

The 2025 Alzheimer's Association guidelines establish a revolutionary paradigm shift: Alzheimer's disease is now defined as a biological disease diagnosed by biomarkers, not clinical symptoms alone, and blood-based biomarkers meeting specific performance thresholds can replace CSF or amyloid PET for confirming AD pathology before initiating disease-modifying therapies. 1, 2

Diagnostic Framework: The Biomarker-First Approach

Blood-Based Biomarkers as First-Line Diagnostic Tools

The most significant update is the validation of blood-based biomarkers (BBMs) for clinical use. BBMs with ≥90% sensitivity and ≥90% specificity can substitute for amyloid PET or CSF testing in patients with cognitive impairment presenting to specialized memory clinics. 2 This represents a fundamental shift from invasive testing to accessible blood tests.

Specific BBM analytes meeting these thresholds include:

  • Plasma p-tau217 (phosphorylated tau-217)
  • Ratio of p-tau217 to non-p-tau217 ×100 (%p-tau217)
  • Plasma p-tau181
  • Plasma p-tau231
  • Ratio of Aβ42 to Aβ40

Critical caveat: Many commercially available BBM tests do NOT meet these performance thresholds, especially using single cutoffs. Clinicians must verify the specific test's diagnostic accuracy before clinical use. 2

Algorithmic Approach to Biomarker Testing

For patients with established cognitive impairment (MCI or dementia) in specialty care settings:

  1. Initial evaluation: Structured history covering cognition, daily function, mood/behavior, and sensorimotor function, plus collateral informant input 1

  2. Structural imaging first: Brain MRI or CT to exclude other pathologies and assess neurodegeneration patterns 1

  3. Biomarker confirmation pathway:

    • Option A (Preferred for accessibility): High-performance BBM test (≥90% sensitivity/specificity) to confirm amyloid pathology 2
    • Option B: CSF analysis for Aβ42 and tau/p-tau if diagnostic uncertainty persists after structural imaging 1
    • Option C: Amyloid PET if uncertainty remains after structural imaging and/or CSF testing 1

Key principle: CSF biomarker results directly impact medical decision-making for disease-modifying therapies and are sufficient for establishing amyloid-beta pathology, which MUST be confirmed before initiating treatment. 1 BBMs meeting performance thresholds now serve this same confirmatory role. 2

When to Use FDG PET or SPECT

FDG PET should be considered when diagnostic uncertainty persists after structural imaging, particularly to differentiate AD from frontotemporal dementia or other non-AD dementias. Avoid FDG PET in advanced dementia stages as it shows diffuse global hypometabolism regardless of cause. 1 SPECT can substitute when FDG PET is unavailable. 1

Disease-Modifying Therapy Eligibility

Mandatory Prerequisites

Before initiating any disease-modifying therapy:

  • Confirmed presence of amyloid-beta pathology via BBM (≥90% sensitivity/specificity), CSF biomarkers, or amyloid PET 1, 2
  • Established cognitive-behavioral syndrome (MCI or mild dementia stage)
  • Comprehensive evaluation ruling out other contributing pathologies

Biological Staging System

The 2024 revised NIA-AA criteria introduce biological staging independent of clinical symptoms 3:

Core 1 biomarkers (early-changing):

  • Amyloid PET, CSF, or high-accuracy plasma biomarkers (especially p-tau217)
  • Abnormal Core 1 biomarker = sufficient to diagnose AD biologically

Core 2 biomarkers (later-changing):

  • Tau PET and additional biofluid markers
  • Provide prognostic information and increase confidence AD is causing symptoms

Clinical staging runs parallel:

  • Stage 0: Asymptomatic with genetic risk, no biomarker abnormality
  • Stage 1: Asymptomatic with biomarker evidence
  • Stage 2: Transitional cognitive decline (including subjective complaints)
  • Stage 3: MCI
  • Stage 4: Mild dementia
  • Stage 5: Moderate dementia
  • Stage 6: Severe dementia

Critical Implementation Considerations

Pretest Probability Matters

Biomarker interpretation requires considering:

  • Age (amyloid and tau pathology increase with age even without clinical AD)
  • Clinical presentation and risk profile
  • Possibility of multiple pathologies (common in older adults)
  • Atypical presentations (early MCI, logopenic variant primary progressive aphasia)

BBMs are most useful when diagnostic confidence is intermediate, not when diagnosis is already clear or highly unlikely. 1, 2

Population-Level Limitations

Do NOT use BBMs for:

  • Asymptomatic population screening (not recommended) 4
  • Primary care settings without specialty consultation 5, 6
  • Populations not represented in validation studies (performance may vary by race, ethnicity, comorbidities) 5, 6

Common Pitfalls to Avoid

  1. Using low-performance BBM tests: Verify your specific test meets ≥90% sensitivity/specificity thresholds 2

  2. Ignoring copathologies: Vascular disease, Lewy body pathology, TDP-43 proteinopathy commonly coexist. Biomarkers for these are emerging but not yet clinically validated (except alpha-synuclein seed amplification assays for Lewy body disease). 1

  3. Misinterpreting indeterminate results: Not all results are clearly positive or negative; intermediate values require clinical judgment and may necessitate additional testing 2, 6

  4. Bypassing comprehensive clinical evaluation: Biomarkers do NOT replace thorough cognitive assessment, functional evaluation, and neurologic examination 2

Emerging Paradigms

Multi-threshold testing and biomarker combinations are evolving approaches that may further refine diagnostic accuracy beyond single-cutoff strategies. 2 Plasma GFAP (glial fibrillary acidic protein) reflects astrocytic activation and adds prognostic value. 1 Neurofilament light chain indicates neurodegeneration but lacks AD specificity. 3

The field is rapidly evolving: Guidelines emphasize the need for living updates as evidence accumulates, particularly regarding BBM performance in diverse real-world populations and optimal biomarker combinations. 2, 6

Practical Workflow for Specialty Care

Step 1: Patient presents with cognitive complaints to memory clinic

Step 2: Obtain structured history (patient + informant), perform mental status examination and dementia-focused neurologic exam

Step 3: Order brain MRI to exclude structural lesions and assess atrophy patterns

Step 4: If AD suspected but diagnostic uncertainty remains, order high-performance BBM test (p-tau217 preferred) 2

Step 5: If BBM positive and clinical syndrome consistent with AD:

  • Diagnose AD biologically
  • Stage clinically (MCI vs. mild dementia)
  • Discuss disease-modifying therapy eligibility
  • Consider Core 2 biomarkers (tau PET) for prognostic information if needed

Step 6: If BBM negative, consider alternative diagnoses or proceed to CSF/amyloid PET if clinical suspicion remains high

Step 7: If BBM indeterminate or unavailable, proceed to CSF testing or amyloid PET per appropriate use criteria 1

This algorithmic approach prioritizes patient outcomes by enabling earlier, more accurate diagnosis and timely access to disease-modifying therapies while avoiding unnecessary invasive procedures through validated blood tests.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.